These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32707032)

  • 1. The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.
    Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Turk J Urol; 2020 Sep; 46(5):360-366. PubMed ID: 32707032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1063. PubMed ID: 32728379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
    Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CAPRA score vs minimal residual disease as predictors of biochemical recurrence after radical prostatectomy.].
    Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Arch Esp Urol; 2021 Jul; 74(6):554-563. PubMed ID: 34219057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
    Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
    Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
    Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Turk J Urol; 2017 Dec; 43(4):456-461. PubMed ID: 29201508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.
    Murray NP; Aedo S; Reyes E; Fuentealba C; Jacob O
    Ecancermedicalscience; 2016; 10():671. PubMed ID: 27610197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer.
    Murray NP; Reyes E; Salazar A; Lopez MA; Orrego S; Guzman E
    Turk J Urol; 2020 May; 46(3):186-195. PubMed ID: 32401703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone.
    Murray NP; Aedo S; Villalon R; Albarran V; Orrego S; Guzman E
    Ecancermedicalscience; 2020; 14():1119. PubMed ID: 33209110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance.
    Murray NP; Reyes E; Fuentealba C; Aedo S; Jacob O
    Ecancermedicalscience; 2017; 11():711. PubMed ID: 28144285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.